Tuesday, April 3rd, 2012 - Wholesale Investor
Company to present at Wholesale Investor Capital Showcase in Brisbane on April 4.

NZ-based health products company Mesynthes has agreed international distribution rights with its North American partner as it gears up for the commercial launch of its proprietary Endoform soft tissue reconstruction technology later this year.

Mesynthes chief executive Brian Ward says the US partner, which he cannot name at present, extended its marketing and sales rights from North America to internationally in March.

The agreement comes as Mesynthes’ manufacturing facility in Wellington was awarded the ISO 13485 accreditation in January, achieving the international medical device manufacturing standard.

“Meeting those standards and extending the agreement with our partner puts us in a good position to launch the product on the international market in the second half of this year,” says Brian Ward.

Mesynthes is a soft-tissue reconstruction company using its proprietary Endoform technology to develop regenerative tissue substitutes for reconstructive surgery and wound care. These markets represent an opportunity in excess of US$1B.

Mesynthes gained 510k marketing clearance from the United States FDA in January 2010 for Endoform™ Dermal Template for acute and chronic wounds.

In March 2011, the company secured a North American marketing and distribution agreement with a major healthcare multinational for their first Endoform based product and they have also entered into a development agreement with another major wound care multinational.

The company will present to investors at the upcoming Wholesale Investor Capital Showcase in Brisbane on April 4.

Meet the CEO of Mesynthes at the Wholesale Investor Capital Showcase

Event Details:

Date: Wednesday 4th of April, 2012

Time: 12.30pm to 4.30pm

Venue: PwC Offices, Brisbane Riverside

Cost: Registration is free. Limited places, register today

Catering: Drinks and canapés served throughout the afternoon

For information go to
http://www.wholesaleinvestor.com.au/smallcapshowcase.php

Hear from renowned industry experts and sector authorities including:

Steve Baxter - Co-Founder of PIPE Networks, Advisory Board of ASX Listed Vocus Communications (ASX:VOC) and Active Investor

Mark Harvey - Partner of CM Capital

Scott Power - Senior Analyst of RBS Morgans

Glenn Cross - COO of AusBiotech

About Mesynthes

Mesynthes is a soft-tissue reconstruction company using its proprietary Endoform technology to develop regenerative tissue substitutes for reconstructive surgery and wound care. These markets represent an opportunity in excess of US$1B.
About Wholesale Investor

Contact Profile

Wholesale Investor


Wholesale Investor is Australia's leading private investment platform showcasing Private, Pre-IPO and Life Sciences ASX Listed Opportunities to over 9200 High Net Worth, Professional and International investors.
Steve Torso, Managing Director, Wholesale Investor
P: 1300 597 595
W: www.wholesaleinvestor.com.au

Keywords

health products, soft tissue reconstruction

Categories

Sharing

More Formats